Organon Company Leadership
| OGN Stock | USD 14.89 0.40 2.62% |
Organon employs about 10 K people. The company is managed by 16 executives with a total tenure of roughly 23334 years, averaging almost 1458.0 years of service per executive, having 625.0 employees per reported executive. Analysis of Organon's management performance can provide insight into the firm performance.
Organon |
Organon Management Team Effectiveness
The company has Return on Asset of 0.0791 % which means that on every $100 spent on assets, it made $0.0791 of profit. This is way below average. Organon's management efficiency ratios could be used to measure how well Organon manages its routine affairs as well as how well it operates its assets and liabilities.Organon Workforce Comparison
Organon Co is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 731,315. Organon claims roughly 10,000 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Net Profit Margin of 0.2 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.25 %, which entails that for every 100 dollars of revenue, it generated $0.25 of operating income. Organon Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organon insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organon's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Organon insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Daniel Karp six days ago Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 | ||
Daniel Karp over a week ago Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 | ||
Daniel Karp over a week ago Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 | ||
Daniel Karp over a week ago Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 | ||
Daniel Karp over a week ago Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 | ||
Daniel Karp over a week ago Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 | ||
Daniel Karp over a week ago Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 | ||
Daniel Karp over a week ago Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 |
Organon Notable Stakeholders
An Organon stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Organon often face trade-offs trying to please all of them. Organon's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Organon's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Matthew Walsh | Executive CFO | Profile | |
| Matthew CFA | Executive CFO | Profile | |
| Meghan Rivera | US Director | Profile | |
| Kirke Weaver | General VP | Profile | |
| Susan ONeal | Chief Officer | Profile | |
| Rebecca Edwards | Chief Officer | Profile | |
| Rachel Stahler | Executive Officer | Profile | |
| Susanne Fiedler | Executive Officer | Profile | |
| Daniel Karp | Executive Development | Profile | |
| Aaron Falcione | Executive Officer | Profile | |
| Geralyn Ritter | Sustainability Affairs | Profile | |
| Kevin Ali | CEO Director | Profile | |
| Jennifer Halchak | Vice Relations | Profile | |
| Joseph Morrissey | Executive Supply | Profile | |
| Vittorio Nisita | Executive Services | Profile | |
| MD JD | Ex RD | Profile |
About Organon Management Performance
The success or failure of an entity such as Organon often depends on how effective the management is. Organon management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Organon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Organon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Organon Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Organon Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon CO operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 9300 people.
Organon Workforce Analysis
Traditionally, organizations such as Organon use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Organon within its industry.Organon Manpower Efficiency
Return on Organon Manpower
| Revenue Per Employee | 626.3K | |
| Revenue Per Executive | 391.4M | |
| Net Income Per Employee | 102.3K | |
| Net Income Per Executive | 63.9M | |
| Working Capital Per Employee | 159K | |
| Working Capital Per Executive | 99.4M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.